NAUTILUS BIOTECHNOLGY INC (NAUT) — insider trading
Health Care · NASDAQ
NAUTILUS BIOTECHNOLGY INC (NAUT) has 13 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 2 open-market sales among the most recent 13 (latest 2026-06-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Epperly Melissa B, | Director | Grant / award / vesting (derivative) | 45,000 | — | $0 | Form 4 |
| 2026-06-18 | McIlwain Matthew S | Director | Grant / award / vesting (derivative) | 45,000 | — | $0 | Form 4 |
| 2026-06-18 | Akinsanya Karen | Director | Grant / award / vesting (derivative) | 45,000 | — | $0 | Form 4 |
| 2026-06-18 | NAZEM FARZAD | Director | Grant / award / vesting (derivative) | 45,000 | — | $0 | Form 4 |
| 2026-06-18 | Posard Matthew L. | Director | Grant / award / vesting (derivative) | 45,000 | — | $0 | Form 4 |
| 2026-06-02 | AH Equity Partners Bio II, L.L.C.; Andreessen Horowitz LSV Fund II, L.P.; AH Bio Fund II, L.P.; AH Equity Partners LSV II, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A | 10% owner | Open-market sale | 384,026 | $2.35 | $902.5K | Form 4 |
| 2026-06-02 | AH Equity Partners Bio II, L.L.C.; Andreessen Horowitz LSV Fund II, L.P.; AH Bio Fund II, L.P.; AH Equity Partners LSV II, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A | 10% owner | Open-market sale | 4,615,974 | $2.35 | $10.85M | Form 4 |
| 2026-03-04 | Patel Sujal M | Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | 25,000 | $2.61 | $65.2K | Form 4 |
| 2026-03-02 | Weld Gwen E | Officer (Chief People Officer) | Grant / award / vesting (derivative) | 160,000 | — | $0 | Form 4 |
| 2026-03-02 | Sankar Subramanian | Officer (Senior VP, Product Development) | Grant / award / vesting (derivative) | 160,000 | — | $0 | Form 4 |
| 2026-03-02 | Patel Sujal M | Director, Officer (CEO, President, and Secretary), 10% owner | Grant / award / vesting (derivative) | 650,000 | — | $0 | Form 4 |
| 2026-03-02 | Mallick Parag | Director, Officer (Chief Scientist), 10% owner | Grant / award / vesting (derivative) | 280,000 | — | $0 | Form 4 |
| 2026-03-02 | Mowry Anna | Officer (CFO and Treasurer) | Grant / award / vesting (derivative) | 160,000 | — | $0 | Form 4 |
Ask the chat about NAUT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: NAUTILUS BIOTECHNOLGY INC (NAUT).
Last updated 2026-06-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.